Journal article
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Abstract
PURPOSE: In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with HER2 overexpressing metastatic breast cancer. We conducted an extension study to this trial to obtain additional safety information and to provide trastuzumab following disease progression.
PATIENTS AND METHODS: A total of 247 patients with documented disease …
Authors
Tripathy D; Slamon DJ; Cobleigh M; Arnold A; Saleh M; Mortimer JE; Murphy M; Stewart SJ
Journal
Journal of Clinical Oncology, Vol. 22, No. 6, pp. 1063–1070
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 15, 2004
DOI
10.1200/jco.2004.06.557
ISSN
0732-183X